<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="2f25af55-9b18-6af6-e063-6294a90a3335"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>Diclona Patch</title>
   <effectiveTime value="20250227"/>
   <setId root="f821869d-f5dd-0fa9-e053-6394a90a8e1a"/>
   <versionNumber value="3"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="078358750"/>
            <name>Terrain Pharmaceuticals</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="2f25e13c-0c3e-9ae8-e063-6294a90a964c"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250227"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="53225-1076" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Diclona Patch</name>
                        <formCode code="C42968" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PATCH"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Lidocaine 4.5%, Diclofenac 1.25%</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="PDC6A3C0OX" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GLYCERIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OZ0E5Y15PZ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ARNICA MONTANA FLOWER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="9G2MAD7J6W" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYACRYLIC ACID (250000 MW)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="506T60A25R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SORBITOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ZY81Z83H0X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ALOE VERA LEAF</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="4PW41QCO2M" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>INDIAN FRANKINCENSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="DO250MG0W6" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DIHYDROXYALUMINUM AMINOACETATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="05I15JNI2J" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM POLYACRYLATE (2500000 MW)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="9H4PO4Z4FT" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DIMETHYL SULFONE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="H4N855PNZ1" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ALPHA-TOCOPHEROL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="g" value="0.0125"/>
                              <denominator unit="g" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="QTG126297Q" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DICLOFENAC SODIUM</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="144O8QL0L1" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>DICLOFENAC</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIR">
                           <quantity>
                              <numerator unit="g" value="0.045"/>
                              <denominator unit="g" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="V13007Z41A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LIDOCAINE HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="98PI200987" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>LIDOCAINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                              <asEquivalentSubstance>
                                 <definingSubstance>
                                    <code code="EC2CNF7XFP" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>LIDOCAINE HYDROCHLORIDE ANHYDROUS</name>
                                 </definingSubstance>
                              </asEquivalentSubstance>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="A2I8C7HI9T" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METHYLPARABEN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6OZP39ZG8H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYSORBATE 80</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="1" unit="g"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C82332" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PATCH"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="3" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code/>
                                    <formCode code="C43200" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="POUCH"/>
                                    <asContent>
                                       <quantity>
                                          <numerator value="5" unit="1"/>
                                          <denominator value="1"/>
                                       </quantity>
                                       <containerPackagedProduct>
                                          <code code="53225-1076-1" codeSystem="2.16.840.1.113883.6.69"/>
                                          <formCode code="C43178" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOX"/>
                                       </containerPackagedProduct>
                                       <subjectOf>
                                          <marketingAct>
                                             <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                             <statusCode code="completed"/>
                                             <effectiveTime>
                                                <low value="20220331"/>
                                                <high value="20250831"/>
                                             </effectiveTime>
                                          </marketingAct>
                                       </subjectOf>
                                    </asContent>
                                 </containerPackagedProduct>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <code code="C73627" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="unapproved drug other"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="completed"/>
                           <effectiveTime>
                              <low value="20220331"/>
                              <high value="20250831"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38304" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TOPICAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="id_link_de0a82ca-31ef-c41b-e053-2a95a90ad0e2">
               <id root="f821b015-0f7a-5f4b-e053-6394a90adfe2"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">Diclona Patch</content>
                     <br/>
                  </paragraph>
                  <paragraph>(Diclofenac Sodium 1.25%, Lidocaine 4.5%)</paragraph>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
               </text>
               <effectiveTime value="20230330"/>
            </section>
         </component>
         <component>
            <section ID="id_link_de0a9cd4-3bce-6d59-e053-2a95a90a6680">
               <id root="f821af5d-3afa-c217-e053-6294a90a0d5d"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>DESCRIPTION</title>
               <text>
                  <paragraph>Diclona Patch (Diclofenac Sodium 1.25%, Lidocaine 4.5%) is a topical pain relief patch containing local arthritis reliever 1.25% Diclofenac Sodium and local anesthetic Lidocaine 4.5%.</paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="bold">Inactive Ingredients: </content>Aloe Vera Gel, Arnica Extract, Boswellia Extract, Dihydroxyaluminum Aminoacetate, Dimethyl Sulfone, Glycerol, Methylparaben, Polyacrylic Acid, Polysorbate 80, Pure Water, Sodium Polyacrylate, Sorbitol, Vitamin E.
 </paragraph>
               </text>
               <effectiveTime value="20230330"/>
            </section>
         </component>
         <component>
            <section ID="id_link_de0a9c13-b202-8657-e053-2995a90a1f97">
               <id root="f8214bfb-68b5-4ddc-e053-6394a90ae13e"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>CLINICAL PHARMACOLOGY</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Pharmacodynamics</content>
                  </paragraph>
                  <paragraph>Lidocaine is an amide-type local anesthetic agent. The penetration of lidocaine into intact skin after application of Diclona Patch is sufficient to produce analgesic effect, but less than the amount necessary to produce a complete sensory block. The mechanism of action of diclofenac sodium in the treatment of actinic keratoses (AK) is unknown. The contribution to efficacy of individual components of the vehicle has not been established.</paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="bold">Pharmacokinetics</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Absorption</content>
                  </paragraph>
                  <paragraph>The amount of lidocaine systemically absorbed from Diclona Patch is directly related to both the duration of application and the surface area over which it is applied. When Diclona Patch is applied topically, diclofenac sodium is absorbed into the epidermis. The systematic bioavailability after topical application of diclofenac sodium is lower than after oral dosing.</paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="bold">Distribution</content>
                  </paragraph>
                  <paragraph>At concentrations produced by application of Diclona Patch, approximately 70% of the lidocaine dose is reported to be bound to plasma proteins, primarily alpha-1-acid glycoprotein. At higher plasma concentrations (1 to 4 mcg/mL of free base), the plasma protein binding of lidocaine is concentration dependent. Diclofenac sodium binds tightly to serum albumin.</paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="bold">Metabolism</content>
                  </paragraph>
                  <paragraph>It is not known if Diclona Patch is metabolized in the skin. Metabolism of diclofenac sodium following topical administration is thought to be similar to that after oral administration. The small amounts of diclofenac sodium and its metabolites appearing in the plasma following topical administration makes the quantification of specific metabolites imprecise.</paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="bold">Excretion</content>
                  </paragraph>
                  <paragraph>Lidocaine and its metabolites are excreted by the kidneys. Less than 10% of lidocaine is excreted unchanged. The half-life of lidocaine elimination from the plasma following IV administration is 81 to 149 minutes (mean 107 ± 22 SD, n = 15). The systemic clearance is 0.33 to 0.90 L/min (mean 0.64 ± 2 max max 0.18 SD, n = 15). Diclofenac sodium and its metabolites are excreted mainly in the urine after oral dosing.</paragraph>
                  <paragraph/>
               </text>
               <effectiveTime value="20230330"/>
            </section>
         </component>
         <component>
            <section ID="id_link_de0aae80-f6a8-0a57-e053-2a95a90a2fe7">
               <id root="f8214bfb-68b6-4ddc-e053-6394a90ae13e"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>INDICATION AND USAGE</title>
               <text>
                  <paragraph>Diclona Patch is indicated for relief of pain associated with arthritis, backache, cramps, discomfort, neckache, soreness, sprains, strains. It should be applied only to intact skin. Sun avoidance is indicated during therapy.</paragraph>
               </text>
               <effectiveTime value="20230330"/>
            </section>
         </component>
         <component>
            <section ID="id_link_de0aa88e-615d-02ff-e053-2995a90af0b2">
               <id root="f8212ad2-2674-2f67-e053-6294a90a634e"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Diclona Patch is contraindicated in patients with a known history of sensitivity to local anesthetics of the amide type, or to any other component of the product. Diclona Patch is contraindicated in patients with a known hypersensitivity to diclofenac sodium. Diclona Patch is contraindicated in patients in the setting of coronary artery bypass graft (CABG) surgery.</paragraph>
               </text>
               <effectiveTime value="20230330"/>
            </section>
         </component>
         <component>
            <section ID="id_link_de0abdee-53be-30b4-e053-2995a90acacc">
               <id root="f8214808-4549-85af-e053-6294a90a3b17"/>
               <code code="34071-1" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS SECTION"/>
               <title>WARNINGS</title>
               <text>
                  <paragraph>Medicines intended to be applied to the skin should not be swallowed.</paragraph>
                  <paragraph>Diclona Patch is flammable. Keep away from open flame.</paragraph>
                  <paragraph>You should never heat, microwave, or add the medicine to hot water.</paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="bold">Risk of Methemoglobinemia</content>
                  </paragraph>
                  <paragraph>Cases of methemoglobinemia have been reported in association with lidocaine use.  Although all patients are at risk for methemoglobinemia, patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, infants under 6 months of age, and concurrent exposure to oxidizing agents or their metabolites are more susceptible to developing the condition. If lidocaine must be used in these patients, close monitoring for symptoms and signs of methemoglobinemia is recommended. Signs of methemoglobinemia may occur immediately or may be delayed some hours after exposure and are characterized by a cyanotic skin discoloration and/or abnormal coloration of the blood.</paragraph>
                  <paragraph>Methemoglobin levels may continue to rise; therefore, immediate treatment is required to avert more serious central nervous system and cardiovascular adverse effects, including seizures, coma, arrhythmias, and death.</paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="bold">Risk of Serious Cardiovascular Events</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Cardiovascular Thrombotic Events</content>
                  </paragraph>
                  <paragraph>Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use.</paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="bold">Fetal Toxicity</content>
                  </paragraph>
                  <paragraph>Avoid use of NSAIDs in pregnant women at about 30 weeks gestation and later. NSAIDs increase the risk of premature closure of the fetal ductus arteriosus at approximately this gestational age. Use of NSAIDs at about 20 weeks gestation or later in pregnancy may cause fetal renal dysfunction leading to oligohydramnios and, in some case, neonatal renal impairment. If NSAID treatment is necessary between about 20 weeks and 30 weeks gestation, limit Diclona Patch use to the lowest effective dose and shortest duration possible.</paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="bold">Serious Skin Reactions</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Drug Rash with Eosinophilia and Systemic Symptoms (DRESS)</content>
                  </paragraph>
                  <paragraph>Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) has been reported in patients taking NSAIDs such as Diclona Patch. DRESS typically, although not exclusively, presents with fever, rash, lymphadenopathy, and/or facial swelling.</paragraph>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="bold">Heart Failure and Edema</content>
                  </paragraph>
                  <paragraph>The Coxib and traditional NSAID Trialists’ Collaboration meta-analysis of randomized controlled trials demonstrated an approximately two-fold increase in hospitalizations for heart failure in COX-2 selective-treated patients and nonselective NSAID-treated patients compared to placebo-treated patients. Avoid the use of Diclona Patch in patients with severe heart failure unless benefits are expected to outweigh the risk of worsening heart failure. If Diclona Patch is used in patients with severe heart failure, monitor patients for signs of worsening heart failure.</paragraph>
               </text>
               <effectiveTime value="20230330"/>
            </section>
         </component>
         <component>
            <section ID="id_link_de0acea7-bc61-4fda-e053-2a95a90aa4dc">
               <id root="f8215b24-c2ff-05b3-e053-6294a90a10d1"/>
               <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
               <title>PRECAUTIONS</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">General</content>
                  </paragraph>
                  <paragraph>Diclona Patch should be used with caution in patients with active gastrointestinal ulceration or bleeding and severe renal or hepatic impairments. Diclona Patch should not be applied to open skin wounds, infections, or exfoliative dermatitis.</paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="bold">Hepatic Disease</content>
                  </paragraph>
                  <paragraph>Patients with severe hepatic disease are at greater risk of developing toxic blood concentrations of lidocaine, because of their inability to metabolize lidocaine normally.</paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="bold">Allergic Reactions</content>
                  </paragraph>
                  <paragraph>Patients allergic to para-aminobenzoic acid derivatives (procaine, tetracaine, benzocaine, etc.) have not shown cross sensitivity to lidocaine. However, Diclona Patch should be used with caution in patients with a history of drug sensitivities, especially if the etiologic agent is uncertain.</paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="bold">Non-intact Skin</content>
                  </paragraph>
                  <paragraph>Application to broken or inflamed skin, although not tested, may result in higher blood concentrations of lidocaine from increased absorption. Diclona Patch is only recommended for use on intact skin.</paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="bold">External Heat Sources</content>
                  </paragraph>
                  <paragraph>Placement of external heat sources, such as heating pads or electric blankets, over Diclona Patch is not recommended as this has not been evaluated and may increase plasma lidocaine levels.</paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="bold">Eye Exposure</content>
                  </paragraph>
                  <paragraph>The contact of Diclona Patch with eyes, although not studied, should be avoided based on the findings of severe eye irritation with the use of similar products in animals.  If eye contact occurs, immediately wash out the eye with water or saline and protect the eye until sensation returns.</paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="bold">Information for Patients Methemoglobinemia</content>
                  </paragraph>
                  <paragraph>Inform patients that use of local anesthetics may cause methemoglobinemia, a serious condition that must be treated promptly. Advise patients or caregivers to stop use and seek immediate medical attention if they or someone in their care experience the following signs or symptoms: pale, gray, or blue colored skin (cyanosis); headache; rapid heart rate; shortness of breath; lightheadedness; or fatigue.</paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="bold">Drug Interactions</content>
                  </paragraph>
                  <paragraph>Specific interaction studies between Diclona Patch and other topical or oral agents were not performed.</paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="bold">Oral Nonsteroidal Anti-Inflammatory Drugs</content>
                  </paragraph>
                  <paragraph>Although low, there is systemic exposure to diclofenac sodium following labeled use of Diclona Patch. Therefore, concomitant administration of Diclona Patch with oral NSAIDs or aspirin may result in increased NSAID adverse effects.</paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="bold">Antiarrhythmic Drugs</content>
                  </paragraph>
                  <paragraph>Diclona Patch should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic.</paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="bold">Local Anesthetics</content>
                  </paragraph>
                  <paragraph>When Diclona Patch is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.</paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph/>
                  <paragraph/>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="bold">Drugs That May Cause Methemoglobinemia When Used with Diclona Patch</content>
                  </paragraph>
                  <paragraph>Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics:</paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="bold">Examples of Drugs Associated with Methemoglobinemia:</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="italics">Class Examples</content>
                     </content>
                  </paragraph>
                  <paragraph>Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics</paragraph>
                  <paragraph>articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine</paragraph>
                  <paragraph>Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase, antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides, antimalarials chloroquine, primaquine anticonvulsants, phenobarbital, phenytoin, sodium valproate, opher drugs acetaminophen, metoclopramide, quinine, sulfasalazine carcinogenesis, mutagenesis.</paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="bold">Impairment of Fertility</content>
                  </paragraph>
                  <paragraph>The effect of Diclona Patch on fertility has not been studied.</paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="bold">Pregnancy</content>
                  </paragraph>
                  <paragraph>Teratogenic Effects</paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="bold">Pregnancy Category B.</content>
                  </paragraph>
                  <paragraph>Diclona Patch has not been studied in pregnancy.</paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="bold">Labor and Delivery</content>
                  </paragraph>
                  <paragraph>Diclona Patch has not been studied in labor and delivery.</paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="bold">Nursing Mothers</content>
                  </paragraph>
                  <paragraph>Diclona Patch has not been studied in nursing mothers.</paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="bold">Pediatric Use</content>
                  </paragraph>
                  <paragraph>Safety and effectiveness in pediatric patients have not been established.</paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="bold">Geriatric Use</content>
                  </paragraph>
                  <paragraph>Reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.</paragraph>
                  <paragraph/>
               </text>
               <effectiveTime value="20230330"/>
            </section>
         </component>
         <component>
            <section ID="id_link_de0acea7-bc64-4fda-e053-2a95a90aa4dc">
               <id root="f8215b24-c300-05b3-e053-6294a90a10d1"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>ADVERSE REACTIONS</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Application Site Reactions</content>
                  </paragraph>
                  <paragraph>During or immediately after treatment with Diclona Patch, the skin at the site of application may develop blisters, bruising, burning sensation, depigmentation, dermatitis, discoloration, edema, erythema, exfoliation, irritation, papules, petechia, pruritus, vesicles, or may be the locus of abnormal sensation. These reactions are generally mild and transient, resolving spontaneously within a few minutes to hours.</paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="bold">Other Adverse Events</content>
                  </paragraph>
                  <paragraph>Due to the nature and limitation of spontaneous reports in post marketing surveillance, causality has not been established for additional reported adverse events including:</paragraph>
                  <paragraph/>
                  <paragraph>Asthenia, confusion, disorientation, dizziness, headache, hyperesthesia, hypoesthesia, lightheadedness, metallic taste, nausea, nervousness, pain exacerbated, paresthesia, somnolence, taste alteration, vomiting, visual disturbances such as blurred vision, flushing, tinnitus, and tremor.</paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph/>
                  <paragraph/>
                  <paragraph/>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="bold">Systemic (Dose-Related) Reactions</content>
                  </paragraph>
                  <paragraph>Systemic adverse reactions following appropriate use of Diclona Patch are unlikely, due to the small dose absorbed (see CLINICAL PHARMACOLOGY, Pharmacokinetics). Systemic adverse effects of lidocaine is similar in nature to those observed with other amide local anesthetic agents, including CNS excitation and/or depression (light headedness, nervousness, apprehension, euphoria, confusion, dizziness, drowsiness, tinnitus, blurred or double vision, vomiting, sensations of heat, cold or numbness, twitching, tremors, convulsions, unconsciousness, respiratory depression and arrest). Excitatory CNS reactions may be brief or not occur at all, in which case the first manifestation may be drowsiness merging into unconsciousness. Cardiovascular manifestations may include bradycardia, hypotension and cardiovascular collapse leading to arrest.</paragraph>
               </text>
               <effectiveTime value="20230330"/>
            </section>
         </component>
         <component>
            <section ID="id_link_de0acb0a-6744-0f6f-e053-2a95a90aaaf6">
               <id root="f8216add-97fd-100d-e053-6294a90a9aaa"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>OVERDOSAGE</title>
               <text>
                  <paragraph>Lidocaine overdose from cutaneous absorption is rare but could occur. Excessive dosing by applying Diclona Patch to larger areas could result in increased absorption of lidocaine and high blood concentrations, leading to serious adverse effects (see ADVERSE REACTIONS, Systemic Reactions). Longer duration of application of more than the recommended number of doses, smaller patients, or impaired elimination may all contribute to increased blood concentration of lidocaine. Due to the low systemic absorption of topically-applied diclofenac sodium, overdosage of diclofenac sodium is unlikely.</paragraph>
               </text>
               <effectiveTime value="20230330"/>
            </section>
         </component>
         <component>
            <section ID="id_link_de0ae1b8-3ae0-36e5-e053-2995a90a6f58">
               <id root="f8216eac-9425-33e0-e053-6294a90a1517"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph>Apply Diclona Patch to intact skin to cover the most painful area. Clean and dry the affected area. Apply product directly to your skin, up to 2 times daily. Diclona Patch should not be worn for longer than 12 hours per application. Clothing may be worn over the area of application. Patches may be cut into smaller sizes with scissors prior to removal of the protective film.</paragraph>
                  <paragraph/>
                  <paragraph>If irritation or a burning sensation occurs during application, wash the product off your skin and do not reapply until the irritation subsides.</paragraph>
                  <paragraph/>
                  <paragraph>When Diclona Patch is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.</paragraph>
               </text>
               <effectiveTime value="20230330"/>
            </section>
         </component>
         <component>
            <section ID="id_link_de0ae544-0c6c-afe2-e053-2a95a90a4044">
               <id root="f821789c-2594-f8d6-e053-6394a90a799b"/>
               <code code="69763-1" codeSystem="2.16.840.1.113883.6.1" displayName="DISPOSAL AND WASTE HANDLING"/>
               <title>HANDLING AND DISPOSAL</title>
               <text>
                  <paragraph>Hands should be washed after the handling of Diclona Patch, and eye contact with Diclona Patch should be avoided. Store in a cool, dry place. Do not store patch outside of the sealed pouch bag. Fold used patches so the adhesive side sticks to itself, then safely discard used patches where children and pets cannot access them. Diclona Patch should be kept out of the reach of children.</paragraph>
               </text>
               <effectiveTime value="20230330"/>
            </section>
         </component>
         <component>
            <section ID="id_link_de0ae8f8-33d1-6b06-e053-2a95a90aa9a9">
               <id root="f821789c-2595-f8d6-e053-6394a90a799b"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>HOW SUPPLIED</title>
               <text>
                  <paragraph>Diclona Patch is available as the following:</paragraph>
                  <paragraph>15 patches: 3 patches per re-sealable pouch, 5 total pouches</paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph>NDC 53225-1076-1</paragraph>
                  <paragraph>Store at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F). [See USP Controlled Room Temperature].</paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph>Manufactured for:</paragraph>
                  <paragraph>Terrain Pharmaceuticals</paragraph>
                  <paragraph>Reno, NV 89501</paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph>For more information, contact Terrain Pharmaceuticals: 
  <linkHtml href="mailto:info@terrainrx.com">info@terrainrx.com</linkHtml>
                  </paragraph>
                  <paragraph/>
                  <paragraph>Printed in the U.S.A.</paragraph>
               </text>
               <effectiveTime value="20230330"/>
            </section>
         </component>
         <component>
            <section ID="id_link_de0afa8f-a399-0a7f-e053-2a95a90adf57">
               <id root="f821789c-259b-f8d6-e053-6394a90a799b"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>Principal Display Panel</title>
               <text>
                  <paragraph>Diclona Patch</paragraph>
                  <paragraph>NDC 53225-1076-1</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="img_f821789c-259a-f8d6-e053-6394a90a799b"/>
                  </paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph/>
                  <paragraph/>
               </text>
               <effectiveTime value="20230330"/>
               <component>
                  <observationMedia ID="img_f821789c-259a-f8d6-e053-6394a90a799b">
                     <text>box</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="Diclona Patch Unit Box.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>